Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic neurons within the substantia nigra pars compacta and the presence of protein aggregates in surviving neurons. LRRK2 G2019S mutation is one the major determinant of familial PD cases and leads to late-onset PD with pleomorphic pathology, including alpha-synuclein accumulation and deposition of protein inclusions. LRRK2 binds and phosphorylates N-ethylmaleimide sensitive factor (NSF).
Introduction
Parkinson's disease (PD) is a heterogeneous movement disorder characterized by the progressive degeneration of dopaminergic neurons within the Substantia Nigra pars compacta (SNpc) and the formation of Lewy bodies containing alpha-synuclein in surviving dopaminergic neurons [reviewed in (Cookson 2005a) ]. Mutations in LRRK2 gene (PARK8; OMIM 609007) are linked to late-onset autosomal dominant PD, accounting for up to 13% of familial PD cases compatible with dominant inheritance (Paisan-Ruiz et al. 2008 ) and 1 to 2% of sporadic PD patients (Taylor, Mata, e Farrer 2006) . Clinically and pathologically, the features of LRRK2-associated parkinsonism are often indistinguishable from idiopathic PD, ranging from SNpc neuronal loss only to general neuronal loss with alpha-synuclein, ubiquitin or tau inclusions [reviewed in (Whaley et al. 2006) ].
Phylogenetically the LRRK2 kinase domain belongs to the TKL (tyrosine like kinases) and shows high similarity to Mixed lineage kinases (MLKs) (Marin 2006) . Like MLKs, LRRK2 is a serine/threonine kinase with no detectable tyrosine kinase activity (A.B. West et al. 2007 ). Disease segregating mutations in LRRK2 have been reported in the kinase domain (G2019S, I2020T), the Roc domain (N1347H, R1441C/G) and in the COR domain (Y1699C) [reviewed in (Mata et al. 2005) ]. However despite its relevance in PD, the physiological function of LRRK2 and the meaning of PD-linked mutations are yet to be completely understood. The protein inclusions observed in PD patients may be due to failure of the protein breakdown pathways. Accordingly, the systemic administration of proteasomal inhibitors causes Parkinson-like neuropathological changes, (Pountney et al., 2008) contain more than 90 molecules, including NSF, that we described as LRRK2 interactor (Piccoli et al. 2014 ) and substrate (Belluzzi et al. 2016) . Detergent solubility characterizes proteinaceous aggregates from the biochemical standpoint (Mamais et al. 2013) . We analyzed by western-blotting the SDS soluble fraction prepared from from post-mortem basal ganglia specimens. Interestingly, the yield of NSF in the SDS soluble fraction was higher in sample prepared from idiopathic or G2019S PD patients ( figure 2A-B ). More, we found that NSF decorates a proportion of α-synuclein positive structure in both idiopathic and G2019S PD cases (figure 2C-D). Protein aggregates form high molecular weight (HMW) complexes that are retained by acetate cellulose in the filter retardation assay (Reid et al. 2003) . Filter retardation assay revealed that NSF forms HMW complexes in samples prepared in dopaminergic neurons differentiated from G2019S human neuronal precursor (Reinhardt, Schmid, et al. 2013 ) (figure 2E-F and supplementary 4A-B).
We confirmed the presence of NSF HMW complex in sample prepared from 6-months hG2019S mice brain (figure 2G-H) despite a similar expression of LRRK2 and NSF in the two mice lines (supplementary figure 4C-F). Therefore, we analysed NSF distribution in brain areas obtained from 6-months old wild-type and hG2019S mice. Interestingly, we noticed the presence of NSF positive aggregates in nigral, striatal, hippocampal and cortical section prepared from 6-months hG2019S mice ( figure 2J and supplementary figure 4C) . A well-established feature of protein aggregates is the resistance to proteinase-K digestion (Kheterpal et al. 2001 ). Thus we characterized NSF aggregates by limited proteolysis in 6-months old wild-type and hG2019S mice brain homogenates.
The 100 kDa MW band, corresponding to full length NSF protein, gradually disappeared in samples prepared from wild-type but not from hG2019S mice upon proteinase-K digestion (figure 2K-L).
Protein aggregates appear as perinuclear cluster decorated by LC3 and p62 (Kopito 2000) . By immunofluorescence analysis, we noticed that NSF localizes in somatic structures positive for LC3 and p62 in primary cortical neurons prepared from hG2019S mouse embryos (figure 2M). All together this evidence suggest that LRRK2 G2019S mutation correlates with the deposition of NSF aggregates.
LRRK2 G2019S kinase activity triggers NSF aggregation
Proteins can aggregate upon impairment of proteasome or lysosome activity (Varshavsky, 2017) .
Lysosomal blockade via NH4Cl treatment (5 mM, 2hours) did not induce NSF aggregation (supplementary figure 5A-B ). Instead, proteasome inhibition (10 μM MG-132, 12 hours) increased the amount of high molecular weight (HMW) NSF aggregates in protein samples prepared from DIV14 wild-type neurons. Strikingly, DIV14 hG2019S neurons were characterized by a basal high amount of HMW NSF that did not further increase upon MG-132 treatment ( figure 3A-B ). Thus, we asked whether LRRK2 G2019S might interfere with UPS mediated NSF degradation. First, we assessed UPS functionality in brain sample prepared from 6-months old wild-type and hG2019S mice. By a fluorimetric assay, we reported a comparable UPS proteolytic activity between the genotypes (supplementary figure 5C ). Phosphorylation can affect protein folding and oligomeric state (Metskas e Rhoades 2015) . By performing a differential detergent solubility assay in N2A cells expressing LRRK2 kinase-dead K1906M or LRRK2 G2019S variant treated or not with LRRK2 inhibitor GSK2578215A (GSK, 0.2 μM 2hours), we noticed that NSF solubility is inversely correlated to LRRK2 kinase activity. In particular, the expression of G2019S variant correlated with an increased amount of NSF in the insoluble fraction that was reverted upon LRRK2 kinase inhibition (figure 3C-D). LRRK2 phosphorylates NSF on T645 (Belluzzi et al. 2016) . To further investigate this feature, we generated by site-direct mutagenesis the NSF phosphomimetic variant NSF T645D. NSF T645D effectively mimics phosphorylation as indicated by its augmented ATPase activity (supplementary figure 5D-E), similar to what we previously observed with NSF directly phosphorylated by LRRK2 at T645. A filter retardation assay in HEK293 cells treated or not with MG-132 and expressing NSF wild-type (NSF WT) or the phosphomimetic variant NSF T645D indicated that NSF T645D is prone to aggregation independently from UPS blockade (figure 3E-F). Accordingly, the elution profile upon size-exclusion chromatography indicates that NSF T645D forms higher-molecular weight complexes than the wild-type variant (supplementary figure 5F-G). Structural analysis of the determined structure of NSF (PDB ID: 3J94) revealed that the side chain of T645 is in close proximity to the ATP-binding site on the D2 domain involved in NSF oligomerization (aa 490-744) (figure 3G-H). Interestingly, we noticed that NSF T645D is strongly enriched in the insoluble fraction as suggested by differential detergent solubility (figure 3I-J).
Strikingly, once co-expressed together with HA-NSF wild-type, NSF T645D influenced the solubility of the wild-type protein as well (figure 3I, K). These observations suggested that phosphorylation at T645 triggers NSF aggregation. Protein aggregates are tagged by ubiquitin. In ubiquitin chain, ubiquitin monomer can be conjugated through K6, K11, K27, K29, K33, K48 and K63, having each different chain a peculiar biological function [reviewed in (Akutsu, Dikic, e Bremm 2016) ]. Thus we sought to determine the extent and the nature of ubiquitination occurring on the two NSF variants. To this aim we expressed in HEK293 cells NSF WT and NSF T645D with myc-ubiquitin wild-type or instead expressing arginine (R) instead of lysine (K) 48, 48 and 63 or 48, 63 and 29, respectively. Western-blotting analysis revealed firstly that NSF T645D is strongly decorated by ubiquitin wild-type and undergoes proteolytic cleavage (figure 3L-N and supplementary figure 5H). Next we found that the ubiquitination of NSF wild-type and T645D depend on different lysine residue: while K63 was crucial to allow NSF wild-type ubiquitination, T645D ubiquitination was impaired only upon K29 removal (figure 3O-P). Interestingly, the nature of the ubiquitin chain affected also the proteolytic cleavage of NSF: protein fragmentation was increased in presence of K48R expression and decreased in presence of K63R (figure 3Q-R). All together, these data suggest that LRRK2 phosphorylation at T645 alters NSF biochemical properties and promotes its aggregation.
NSF over-expression is detrimental for hG2019S neurons in a LRRK2 kinase dependent manner.
Protein aggregation is considered the main trigger of neuron death in PD (Cookson 2005b) . To investigate whether NSF aggregation may be neurotoxic, we infected DIV4 wild-type and hG2019S neurons with lentiviral viruses expressing mCherry alone or together with NSF wild-type, the phospho-null variant NSF T645A or the phospho-mimetic variant NSF T645D. Neurons were treated from DIV10 to DIV14 with DMSO or GSK2578215A (GSK, 0.2 μM) and then processed at DIV16 (figure 4A and supplementary figure 6A). Neurite retraction is an established marker of neuronal damage (Chernova et al. 2007 ). Our morphological analyses revealed that the overexpression of either NSF wild-type or T645A had no major effect on wild-type neuron morphology.
Instead, NSF T645D was detrimental to wild-type neurons. Noteworthy, NSF wild-type overexpression caused a significant reduction of neurite number in hG2019S neurons. Such morphological phenotype was absent in hG2019S neurons over-expressing the phospho-null NSF T645A variant. Interestingly, the chronic treatment with the LRRK2 kinase inhibitor GSK2578215A prevented the toxicity due to NSF wild-type over-expression in hG2019S cultures (figure 4B). The analysis of neuronal viability via MTT assay confirmed this outcome ( figure 4D ). Cumulatively, these data indicate that NSF is neurotoxic upon LRRK2 phosphorylation.
Trehalose treatment clears NSF aggregates
Protein aggregation can be attenuated by autophagy induction (Fujikake, Shin, e Shimizu 2018) .
Trehalose is a natural occurring disaccharide that stimulates autophagy in vitro and in vivo (DeBosch et al. 2016) . Trehalose treatment induced autophagy in wild-type and hG2019S neurons (supplementary figure 6B-C). Biochemical analysis by the means of filter retardation assays suggested that trehalose treatment reduced NSF aggregation in NSF over-expressing HEK293 cell treated with MG132 (supplementary figure 6D-E). In vivo trehalose treatment reduced NSF aggregation in 6-months old hG2019S mice (1% in the drinking water, 1-month; supplementary figure 6F-G) without major impact on animal weight (supplementary figure 6H ). Therefore we profiled the presence of NSF aggregates in specimens obtained from 6-month old wild-type and hG2019S mice treated with trehalose (1% in the drinking water, 1-month). Trehalose treatment reduced the number of cells decorated by NSF in substantia nigra (figure 5), striatum (figure 6), cortex and hippocampus (figure 7) region of hG2019S mice. Apoptotic cell death is preceded by caspase-3 cleavage. We noticed a significant increase of cleaved-caspase 3 positive cells in nigra (figure 5) and striatum (figure 6) without any overt loss of TH density. Caspase-3 positive cells were also evident in the cortex and hippocampus (figure 7) of hG2019S mice. Interestingly, we noticed a significant reduction of the number of caspase-3 positive cells in substantia nigra (figure 5), striatum (figure 6), cortex and hippocampus (figure 7) of hG2019S mice upon trehalose treatment. Our observations suggest that trehalose treatment cleared NSF aggregation and reduced cell death in hG2019S mice brain.
Trehalose treatment ameliorates motor and cognitive phenotype in hG2019S mice
Next we profiled motor and cognitive performances in 6-month old hG2019S and wild-type mice upon chronic treatment with trehalose. Noteworthy we reported a robust recovery of motor and cognitive abilities in trehalose-treated animals. In particular, trehalose treatment ameliorated the performances at 6-mm balance beam ( figure 8C ), 32-rpm rotarod (figure 8F), rotarod resistance at 12 rpm (figure 8G) and Novel object recognition ( figure 8H ). We reported a partial improvement in motor and cognitive performances (in the rotarod 32 rpm and in the novel object recognition) also in 12-month old hG2019S mice treated with trehalose starting at month 10 (1% in the drinking water, 2-month; supplementary figure 7). All together, this evidence suggests that trehalose treatment is beneficial in rescuing behavioural defects of hG2019S mice.
Discussion
Our data show that hG2019S mice present an age-dependent motor and cognitive impairment together with the deposition of protein aggregates containing NSF and signs of cell death in substantia nigra, striatum, cortex, and hippocampus. Post-mortem brain investigation demonstrated that LRRK2 G2019S kindred most often show synucleinopathy, occasionally tauopathy, suggesting a role for LRRK2 in protein inclusion pathology (Taymans e Cookson 2010) . It has been shown that LRRK2 kinase activity led to proteins accumulation without affecting the catalytic activity of the proteasome or expression levels of proteasomal core sub complexes (Lichtenberg et al. 2011) .
Instead, LRRK2 influence autophagic pathway at multiple levels [reviewed in (Manzoni e Lewis 2017) . The investigation of LRRK2-deficient mice displayed a biphasic alteration in autophagy in the kidney (Tong et al. 2010a (Tong et al. , 2012 ; however, similar studies in an independent LRRK2-knock out mouse line demonstrated an accumulation of secondary lysosomes in the kidney without a major involvement of autophagy (Herzig et al. 2011a) . Even more complex is the state-of-art describing autophagy in LRRK2 disease context. In fact a number of authors conclude that G2019S mutation increases autophagy in different models, including stable cell lines (Gómez-Suaga, Luzón-Toro, et al. 2012; Plowey et al. 2008) , fibroblasts (Yakhine-Diop et al., 2014) , iPS derived neurons (Bravo-San Pedro et al. 2013) , C.Elegans (Ferree et al., 2012) and mice (Ramonet et al., 2011) . However others studies have reported that the same mutation reduces (Manzoni et al. 2013) or at least does not affect (Sánchez-Danés et al. 2012; Wauters et al. 2019) autophagy. Such conflicting results hinder a clear picture of the impact of LRRK2 G2019S mutation on autophagy (Manzoni 2017) .
Still, increased accumulation of protein aggregates have been reported in complementary LRRK2 G2019S models (Bang et al. 2016; Guerreiro et al. 2016; Novello et al. 2018; Schapansky et al. 2018 ). Thus it might be possible that LRRK2 controls protein clearance acting upstream of the two main protein-clearance machineries. Post-translational modifications regulate protein structure. In particular, phosphorylation can dictate protein folding and eventually aggregation state. In the context of PD, phosphorylation has a severe impact on alpha synuclein [reviewed in (Tenreiro, Eckermann, e Outeiro 2014)]. While soluble, monomeric alpha synuclein is largely not phosphorylated in physiological conditions, up to 90% of LB-synuclein is phosphorylated on Ser-129 (Anderson et al. 2006 ). Indeed it is still unresolved whether phosphorylation might trigger or impair alpha synuclein aggregation or toxicity. In fact, while a number of reports claim that phosphorylation at Ser-129 favours protein aggregation (Kragh et al. 2009; Wu et al. 2011 ) other authors described opposite or no effect (Fiske et al. 2011; Sancenon et al. 2012 ). However, phosphorylation at Ser-129 influences synuclein sub-cellular localization (Gonçalves e Outeiro 2013), suggesting that such PTM dictates synuclein function and fate. Similarly, hyperphosphorylated Tau protein precipitates in toxic aggregates that destabilize axonal tubulin cytoskeleton (Alonso et al. 2018 ). In vitro evidence shows that the phosphorylation of specific Tau residues modifies local folding thus affecting global structure (Bibow et al. 2011; Inoue et al. 2012 ).
Our previous work suggested that LRRK2 phosphorylates NSF on Thr-645 (Belluzzi et al. 2016 ).
Based on our structural analysis, the side chain of T645 falls in proximity to the ATP-binding site on NSF located on the D2 domain (aa 206-477). In particular Thr-645 lies very closely to the phosphate group of the bound ATP molecule. ATP binding on the D2 domain is important for the formation of NSF hexamer (Whiteheart, Schraw, e Matveeva 2001) . We determined by complementary means that upon phosphorylation at Thr-645 NSF forms bona fide HMW aggregates, being insoluble to Triton-X100 (Naslavsky et al. 1997 ), resistant to proteinase-K treatment (Kheterpal et al., 2001) and decorated by ubiquitin and p62 (Bjørkøy et al. 2005) . Indeed it is unlikely that LRRK2-mediated phosphorylation is the unique causative driver for NSF aggregation. In fact, we reported that Rab3A, a well-established LRRK2 substrate (Lis et al. 2018; Steger et al. 2016) does not overtly aggregate in BAC hG2019S mice. Thus, LRRK2 phosphorylation might not be the unique driver promoting NSF aggregation. As reported for other aggregation-prone protein like tau, it is more conceivable that NSF has an intrinsic propensity towards aggregation that is exacerbated upon LRRK2 phosphorylation. Indeed, we reported that NSF decorates a proportion of LB not only in G2019S but also in idiopathic PD patients. This evidence apparently argue against a causative role for LRRK2 kinase activity. However, it has been recently postulated a role for LRRK2 in idiopathic patients (Di Maio et al. 2018) , leaving open the possibility that LRRK2 kinase activity may trigger NSF aggregation also in not genetic cases. But what could be the impact of NSF aggregation? NSF is a key component of presynaptic machinery, allowing the first step of SV recycling (Pallanck et al. 1995) . Numerous studies have shown that depletion of cytosolic NSF impair membrane fusion machinery (Rothman, 1994) and results in accumulation of intracellular vesicles (Malhotra et al. 1988; Mohtashami et al. 2001 ). Thus NSF aggregation might affect presynaptic fusion machinery. Interestingly, it has been reported that experimental ischemia induces NSF aggregation into Triton-X 100 insoluble inclusions that harm neuronal function via sequestering synaptic vesicle (Liu e Hu 2004) . While a presynaptic dysfunction might indeed explain early stage or preclinical manifestation of PD in animal model (Longo et al. 2017; Melrose et al. 2010; Sloan et al. 2016) or in presymptomatic LRRK2 G2019S carriers (Sossi et al. 2010) , it is difficult to envisage how aberrant vesicle release could cause the neuronal loss in the substantia nigra reported in the late phase of the disease. We observed that T645 phosphorylation influences the cellular fate of NSF. In fact our in vitro observations suggest that the ubiquitination of wild-type NSF mainly depends on Lys-63. It has been proposed that Lys-63 linked polyubiquitination promotes the formation of protein inclusions and tags them for subsequent clearance via autophagy (Tan et al. 2008) or proteasome (Ohtake et al. 2018) . Instead, the phosphomimetic T645D variant appears to be decorated by Lys-29 ubiquitin chains, that has been associated with lysosomal degradation (Xu et al. 2009 ). Altogether, our data suggest that the phosphorylation of NSF at T645 favours NSF oligomerization state and eventually triggers its precipitation into protein inclusions with peculiar structural features. Indeed, neurons benefit of several machineries to effectively handle protein aggregation, but the ultimate resource to counteract proteinaceous stress is the degradative clearance of misfolded protein (Rubinsztein 2006 ). However, the structure of the proteasome complex itself disfavours the clearance of large oligomeric and aggregated proteins: substrates need to be unfolded to pass through the tight pore of the proteasome barrel (Verhoef et al. 2002) . Autophagy may help, being capable to handle large protein aggregates (Hara et al. 2006; Komatsu et al. 2006 (Novello et al. 2018 ). Thus, ageing and pathological LRRK2 phosphorylation together may contribute to the deposition of NSF aggregates. Still, given the low stoichiometry that we reported for LRRK2-driven NSF phosphorylation in vitro (Belluzzi et al. 2016) , it may well be that NSF phosphorylation occurs very seldom in vivo. However, we noticed that T465D NSF affects the detergent solubility of the unmodified protein. Thus, we may depict a model where few phosphorylated NSF molecules lead the formation of pathological seeds capable of sequestering unphosphorylated protein into large aggregate that accumulate along ageing. All together this evidence could leave space for a therapeutic strategy targeting LRRK2 kinase activity. Several brain penetrant LRRK2 selective inhibitors have been identified [reviewed in (Hatcher et al. 2017) ]; however the wide expression of LRRK2 in other organs apart from the central nervous system, including lung, kidney and the immune system raise issues about side effects (Baptista et al. 2013; Fuji et al. 2015; Herzig et al. 2011b; Ness et al. 2013; Tong et al. 2010b ). Thus, complementary therapeutic approaches are needed. Targeting NSF aggregates may be clinically relevant. However, it is reasonable to predict that LRRK2 kinase activity affects the biochemical profile of other substrate besides NSF. Thus, a more holistic solution is needed. The activation of autophagy may promote the clearance of toxic protein aggregates. We reported here that chronic treatment trehalose reduced NSF aggregation and ameliorated motor and cognitive phenotype in aged G2019S mice. Treatment with trehalose already demonstrated to be protective in models of Huntington disease, spinocerebellar ataxia and Parkin-PD (Rodríguez-Navarro et al. 2010; Sarkar et al. 2007; Seki et al. 2010 ). However, the pharmacokinetics properties of trehalose are poor. Small intestine, kidney and CNS expression of trehalose catalytic enzyme, trehalase, limits its bio-avalaibility (Halbe e Rami 2019). Also, dietary trehalose results in digestive issues (Montalto et al. 2013 ) and may enhance the virulence of common nosocomial pathogen (Collins et al. 2018 ). These issues severely reduce the possibility to introduce trehalose into the clinical management of PD patients. In conclusion, boosting autophagy may be a powerful therapeutic strategy in LRRK2-PD but a clinically relevant drug is still to be discovered.
Experimental procedures

Animals.
All animal protocols were approved by the University of Trento and National Ministery of Health (IACUC 793/2016-PR). The murine G2019S-LRRK2 BAC mice were previously described (Li et al., 2010) and have been backcrossed onto the C57BL/6J mice for >10 generations.
Animals were kept in a normal light/dark cycle (12 hours light/ 12 hours dark) and had free access to food and water. All procedures involving animals were approved by Institutional agencies (OPBA-Università degli Studi di Trento) and Italian Ministry of Health (Università degli Studi di Trento prot. n. 793/2016-PR).At 5 or 10 months, Wild-type and G2019S-LRRK2 BAC male littermates were divided into trehalose and control groups. In the trehalose group, mice were offered 1% trehalose drinking water solution. The treatment solution was changed every week. In the control group, mice were given drinking water. Mice body weight was measured every week since the start of treatment. Only male mice were used in our experiments.
Assays in post-mortem specimen
In total, 5 idiopathic, 4 G2019S and 5 control human brain cases were used in the study which were obtained from the archives of QSBB following appropriate local ethics committee approval.
Demographic details of the cases have been described previously (Mamais et al. 2013) .
For biochemical analysis, 10μg of TBS soluble fraction of brain homogenates from frontal cortex were run on 10% Bis-tris gels with MOPS as running buffer. Protein from gels were transferred onto PVDF membranes and probed with NSF and beta actin (Sigma, mouse monoclonal) antibodies overnight with shaking. Following incubation with appropriate HRP conjugated secondary antibodies, blots were visualized by enhanced chemiluminencesnce (Pierce; UK) detection. Protein expression levels were determined by densitometry and NSF results normalised to beta-actin levels.
For immunohistochemical evaluation, 8μm substantia nigra sections from 4 PD and 2 G2019S-LRRK2 PD were dewaxed in xylene, and pre-treated with 95% formic acid for 10min to expose antigenic sites. Standard immunohistochemistry protocol was followed using NSF (1:200 mouse monoclonal; SY-SY) and alpha-synuclein (1: 300; rabbit polyclonal, Abcam) primary antibodies with o/n incubation at 4C. Double immunofluorescence was performed using tetramethyl rhodamine labelled secondary antibody for alpha-synuclein and NSF with the fluorescein signal amplification kit (Perkin Elmer, UK). Following adequate washes to remove background fluorescence, sections were mounted with aquamount (Merck, UK). Control sections where primary antibody was omitted displayed no significant background staining. Flourescent signals from sections were scanned using Leica fluorescent microscope (Leica CTR6000). Total alpha-synuclein positive LBs were counted from each section and the proportion of NSF+ve LBs were derived.
Behavioural tests
Spontaneous Motor Activit. Spontaneous motor activity was evaluated in an automated activity cage (43 cm × 43 cm × 32 cm) (Ugo Basile,Varese,Italy) placed in a sound-attenuating room as previously described (Ferri et al. 2004) .Cumulative horizontal and vertical beam breaks were counted for 3 hours.
Balance Beam walking. The beam apparatus consists of 1 meter beams with a flat surface of 12 mm or 6 mm width resting 50 cm above the table top on two poles according to (Luong et al. 2011) . A black box is placed at the end of the beam as the finish point. Nesting material from home cage is placed in the black box to attract the mouse to the finish point. A lamp (with 60 watt light bulb) is used to shine light above the start point and serves as an aversive stimulus. A video camera is set on a tripod to record the performance. On training days, each mouse crosses the 12 mm beam 3 times and then the 6 mm beam 3 times. The time required to cross to the escape box at the other end (80 cm away) is measured with a stopwatch. The stopwatch is started by the nose of the mouse entering the center 80 cm, and stopped when the animal reaches the end of the 80 cm. Once the mice are in the safe box, they are allowed some time (~15 secs) to rest there before the next trial. The mice rest for 10 min in their home cages between training sessions on the two beams. On the test day, the time to cross each beam is recorded. The beams and box are cleaned of mouse droppings and wiped with towels soaked with 70% ethanol and then water before the next beam is placed on the apparatus.
Pole test. In the vertical pole task, the mouse was placed on a vertical wire-mesh pole with its head facing upwards. Mice were habituated to the task in 2 trials per day for 2 days. On test day (third day) mice were subjected to 5 trials: the total time taken to turn the body and to descend was recorded according to (Hickey et al. 2008) . A cut-off of 60 sec was given. Data were shown as mean of 5 trials evaluated during the test day.
Rotarod. The rotarod apparatus (Ugo Basile, Biological Research Apparatus, Varese, Italy) was used to measure fore and hindlimb motor coordination and balance (Dauge et al. 2001) . During the training period, each mouse was placed on the rotarod at a constant speed (12 or 32 rpm) for a maximum of 120 sec, and the latency (sec) to fall off the rotarod, within this time period, was recorded. Mice received four tests/trial each day for 4 consecutive days. The fourth test of each trial was evaluated for statistical analysis. The fifth day mice were submitted to Rotarod resistance at a constant speed (12 rpm) for a maximum of 30 min and the latency (sec) to fall was measured.
Novel object recognition. The novel-object recognition test was performed over a 3-day period in an open plastic arena (60 cm x 50 cm x 30 cm), as previously described (Pan et al. 2008) . Animals were habituated to the test arena for 10 min on the first day. After 1 day habituation, mice were subjected to familiarization (T1) and novel-object recognition (T2). During the initial familiarization stage, two identical objects were placed in the centre of the arena equidistant from the walls and from each other. Each mouse was placed in the centre of the arena between the two objects for 20 min or until it had completed 30 s of cumulative object exploration. Object recognition was scored when the animal was within 0.5 cm of an object with its nose toward the object. Exploration was not scored if a mouse reared above the object with its nose in the air or climbed on an object. Mice were returned to the home cage after familiarization and then tested again after different delays (from 5 min to 24 h later). A novel object (never seen before) took the place of one of the two familiars. Scoring of object recognition was performed in the same manner as during the familiarization phase. From mouse to mouse the role (familiar or new object) as well as the relative position of the two objects were counterbalanced and randomly permuted. The objects for mice to discriminate consisted of white plastic cylinders and coloured plastic Lego stacks of different shapes. The arena was cleaned with 70% ethanol after each trial. An experimenter blind to the genotype group manually recorded the exploration times to the objects for each animal. Total time spent exploring the two objects during T1 and T2 was also calculated.
Cell cultures
Neuron cultures were prepared from mouse cortexes obtained from embryonic day 15.5-16.5 wildtype or hG2019S mice (C57BL/6J) as previously reported (Pischedda e Piccoli 2015; . Briefly, after brain dissection the cortexes were mechanically dissociated after 15 min incubation with 2,5% Trypsin (Euroclone) at 37 °C in agitation. The resulting cells were counted and cryopreserved or directly plated on previously poly-D-lysine (Sigma) coated wells or cover slips, according to the desired density. High density (750-1000 cells/mm2) neuron cultures were plated on 12-well plastic tissue culture plates (Iwaki; Bibby Sterilin Staffordshire, UK) and medium-density (150-200 cells/mm2) onto 12mm diameter cover slips inserted into 24-well plastic tissue culture plates (Iwaki). The cells were grown in Neurobasal at 37°C and 5% CO 2 . Neuronal transfection was carried out using Lipofectamine 2000 (Life Technologies) following the manufacture's instruction. The cells were treated with LRRK2 kinase inhibitor, GSK-2578215A (Tocris Bioscience, Bristol, UK), MG132 (Tocris Bioscience, Bristol, UK) and Trehalose (Sigma) by addition to culture media at the concentrations indicated through the text.
Human embryonic kidney cells (HEK293T) were cultured in DMEM complete: Dulbecco's modified Eagle's medium (DMEM, Euroclone) supplemented with 10% fetal bovine serum (FBS, Euroclone) at 37°C and 5% CO2. HEK293T were transiently transfected using linear polyethylenimine (PEI, Polysciences) with ratio DNA: PEI 0.8:100. 4 µg of DNA were dissolved in 0.5 ml of PEI solution and vortexed for 20 sec. The DNA-PEI mix was incubated for 10 minutes at room temperature (RT) and added directly to the cells. The medium was changed after 24h and the cells were lysed 48h post transfection. Lentiviruses were produced by transient transfection of HEK293T cells according to standard protocols (Wiznerowicz e Trono 2003) . Primary cortical cultures were transduced at DIV4 with lentiviruses at multiplicity of infection 3 (MOI3). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to measure culture viability as described (Mosmann 1983) . High density (750-1000 cells/mm2) neuronal culture were infected at DIV 4 and processed for MTT assay at DIV16. Briefly, MTT ( (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide-Sigma Aldrich) stock solution 20X ( 5mg/ml in MilliQ water) was diluted in neuronal complete media and cells were were incubated with MTT mix for 30 minutes at 37°C with 5% CO2. After incubation, media was discarded, cells were resuspended in DMSO to dissolve the intracellular purple precipitates and the absorbance was measured at 570 nm with the Plate reader Infinite 200 PRO (Tecan Life Sciences). Toxicity was calculated as 1-cell viability, being cell viability expressed as fold over control.
iDA culture
Wild-type, G2019S and G2019S corrected Human iPSCs derived Neuronal Precursors Cells (NPCs) were obtained from Dr. Deleidi lab and cultures as previously reported ). Briefly, the cells were expanded in 50:50 DMEM F12 and Neurobasal medium with: 1% P/S, 1% B27 (without Ascorbic acid), 0,5% N2, 1%L-glutamax, 150 µM Ascorbic acid, 3 µM CHIR, 0.5 µM Purmorphamine (PMA) (NPC expansion medium). Media was changed every other day and cells were passed every week after 10 min incubation with Accutase (200ul/12 well). The cells were re-plated at a 1:10 ratio in 12-well plates pre-coated with Matrigel (1:30 from Stock) in 'NPC expansion medium' supplemented with 10 μ M ROCK inhibitor for the first day after splitting.
After the second passage, when the cells reached 80% of confluency, the media was changed to Ventral CNS differentiation medium (50:50 DMEM F12 and Neurobasal medium with: 1% P/S, 1% B27 (without Ascorbic acid), 0,5% N2, 1%L-glutamax, 100 ng/mL FGF8, 200 µM of Ascorbic acid and 1µM PMA. When confluent the cells were split with Acutase and re-plated in Matrigel coated 6 wells plate at a 1:1 ratio. The media was changed every other day. After 10 days the Ventral CNS differentiation medium I was changed to maturation medium (50:50 DMEM F12 and Neurobasal medium with: 1% P/S, 1% B27 (without Ascorbic acid), 0,5% N2, 1%L-glutamax, 10 ng/mL BDNF, 10 ng/mL GDNF, 1ng/mL TGF-b3, 200 µM ascorbic acid, 500 µM dbcAMP and 0,5 µM PMA). After 48h the media was changed to dopaminergic differentiation medium ( 50:50 DMEM F12 and Neurobasal medium with: 1% P/S, 1% B27 (without Ascorbic acid), 0,5% N2, 1%Lglutamax, 10 ng/mL BDNF, 10 ng/mL GDNF, 1ng/mL TGF-b3, 200 µM ascorbic acid, 500 µM dbcAMP). The cells were kept in dopaminergic differentiation medium until the end of the experiment and the medium was changed every 2-3 days.
Immunohistochemistry
Six and 12 months old mice were anaesthetized and transcardially perfused with PBS 1X followed by 4% paraformaldehyde in PBS 1X. Brains were dissected, postfixed for 2h by immersion in the same fixative and then cryoprotected by immersion in 30% sucrose solution in PBS 1X for 24 h at 4°C. Brains were included in OCT and stored at -80°C until processing. 14 µm brain coronal sections were obtained after serial sectioning on Leica cryostat and mounted on Polysine Slides (Thermo Fischer Scientific). The slices were saturated in 2,5% BSA, 10% NGS, 0,2% Triton X-100, PBS 1X, for 1 hour at RT and incubated with the primary antibody O/N at 4°C. After 3 washes in PBS 1X -0,2% Triton X-100 the sections were quenched for 15 min in PBS 1X plus 0,3% H 2 O 2 at RT, then washed with PBS 1X. The sections were incubated for 30 min with the secondary biotinylated antibody ( at RT . The slices were then rinsed in PBS1X and incubated for 30 minutes with Vectastain ABC kit 1:1 mix (Vectorlab), washed 2 times in PBS 1X -0.2% Triton X-100, washed once in PBS1X, and developed with DAB quanto mix (Thermo Scientific) for 30 sec. The stained sections were rinsed in PBS 1X stained in Hematoxylin solution, Gill No.2 (Sigma Aldrich) for 2,5 minutes and then washed for 2 minutes with tap water. Sections were incubated with differentiation solution (70% ETOH plus 0,3% Hcl) for 10 seconds, washed with tap water and then incubated for 30 seconds with Scott's Tap water Substitute (Sigma Aldrich) for blueing. Sections were then dehydrated, mounted using DPC mounting reagent (Sigma) and kept at RT until acquisition with a Zeiss Axio Imager M2 equipped with 40X objective.
Immunofluorescence
For the immunostaining experiments, neurons were fixed in 4% paraformaldehyde and 4% sucrose at room temperature or 100% methanol at -20°C. mCherry positive neurons were randomly chosen for quantification in at least four independent experiments for each condition. Cover slips were mounted with prolonged reagent (Life Technologies) and observed with Zeiss Observer Z1 microscope equipped with an Apotome module. The obtained images provide an axial resolution comparable to confocal microscopy (Garini, Vermolen, e Young 2005; Schaefer, Schuster, e Schaffer 2004) . Images were acquired with AxioObserv Z1 microscope equipped with Apotome module using a plan-Apochromat 63x/1.40 Oil objective, pixel size 0,102 mm x 0.102 mm. Acquired images were analyzed with ImageJ software using NeuronJ plugin (Meijering et al. 2004 ).
Biochemical assays
Proteinase K digestion. Proteinase K digestion of mouse brain lysates was performed on samples prepared from 6 months mouse LRRK2 wild-type and LRRK2 G2019S brains. Brains were solubilized by mechanical homogenization of 1g of tissue in lysis buffer (150 mM NaCl, 2 mM EDTA, 50mM Tris-HCl, 1% NP-40 and 0.25% sodium deoxycholate, pH 7.4) using a pestle and incubated 1h at 4ºC. Next brain lysates were centrifuged at 14,000xg for 10 min at 4°C to collect supernatant and samples were quantified following Bradford's method. Proteinase K was added to 50 µL of sample (previously prepared at 1µg/µL concentration) at different final concentration ranging from 0.3-0.5 µg/mL and incubated at 37ºC for 25 minutes under shaking. Digestion reactions were stopped by addition of the inhibitor PMSF (4mM) and samples (undigested and exposed to Proteinase K) were prepared in sample buffer 5X for Western-blotting analysis.
Proteasome activity. Proteasome activity in mice brain tissue was analysed following the 20S Proteasome activity assay kit protocol by Millipore (APT280). The assay detects the fluorophore 7-Amino-4-methylcoumarin (AMC) after cleavage from the labelled substrate LLVY-AMC. Briefly, 3 µg of protein from each sample was incubated for 1 h at 37°C with proteasome labeled substrate in 96 dark multiwells. The sensibility of the assay was tested performing serial dilution of proteasome positive control (1:4 to 1:256) of the stock solution in 1X Assay buffer. Fluorescence data was collected using a PE Biosystems CytoFluor 400 plate reader using a 380 nm excitation and 460nm emission filters.
Filter retardation assay. Filter retardation assay were performed as described in (Perez Carrion et al. 2018) . Briefly, cell cultures were rinsed once in cold PBS 1X and mechanically detached in PBS 1 X plus protease and phosphatase inhibitor cocktails Calbiochem (40 µl/well 12 wells plate). Cell samples were sonicated 3 times with 1s pulse and 1s stop sequence at 10% pulse amplitude. Brain extracts from 6 months mouse LRRK2 wild-type and LRRK2 G2019S variant were prepared by mechanical homogenization of 1 gr of tissue in solubilization buffer (150 mM NaCl, 2 mM EDTA, 50mM Tris-HCl, pH 7.4) using a pestle and incubated 1h at 4ºC. Then brain lysates were centrifuged at 14,000xg for 10 min at 4°C to collect supernatant. Protein amounts were quantified following Bradford's method. Ten µg of each sample were diluted to 120 µl in PBS 1X. The samples were immobilized on methanol equilibrated cellulose acetate membrane through a dot blot void system (BioRad).
Streptavidin pull down. Streptavidin pull down was performed as described in ). Briefly, HEK293T cells were transiently transfected and treated as indicated trough the text.
The cells were then resuspended in 5ml ice cold PBS 1X, centrifuged at 150xg for 5 min and lysed in 1 ml of 50mM HEPES pH 7.4, 150mM NaCl, 0.5mM EDTA, 0.5% Triton X-100, protease inhibitors (Calbiochem) and phosphatase inhibitor cocktails II and IV (Calbiochem), after incubation for 1 h at 4°C in rotation. The cell lysate was recovered after 10 min centrifugation at 15000xg at 4°C and 10% of supernatant kept as input. The remaining supernatant was incubated with 25 µl of Streptavidin resin (IBA) for 1 hour at 4°C in rotation. After three washes in 0.5 ml of 50mM HEPES pH 7.4, 150mM NaCl, 0,2% Triton X-100, the bound protein was eluted in 60 µl of Laemmli buffer 1X after 10 min incubation at 52°C. Solubility assay. HEK293T cells were cultivated in 12 well plates and transiently transfected and treated as indicated trough the text. Cells were rinsed with cold PBS1X and then lysed in Triton-X100 buffer at 4°C (50mM HEPES pH 7.4, 150mM NaCl, 1 % Triton X-100, protease inhibitors (Calbiochem) and phosphatase inhibitor cocktails II and IV (Calbiochem)). The cell lysate was kept on ice and briefly vortexed every 10 minutes for 3 times, then centrifuged at 16.000g for 10 minutes at 4°C. The Supernatant was collected as the detergent-soluble fraction and the pellet constituted the insoluble fraction. The pellet was resuspended in 75 ul of Laemmli sample buffer 2X, whereas the same volume of Laemmli sample buffer 5X was added to the soluble fraction.
Protein purification. HEK-293T cells were lysed in lysis buffer [20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM Na4P2O7, 1 mM beta-glycerophosphate, 1mM NaVO4, Protease Inhibitor Mixture (Sigma-Aldrich)] by using a needle. Cleared lysates (1 ml) were incubated with 30 µl of anti-FLAG-M2-agarose beads by rotating overnight at 4°C. Resin complexes were washed with different buffers WB1 (20mM Tris-HCl pH7.5, 500mM NaCl) twice, WB2 (20mM Tris-HCl pH7.5, 350mM NaCl) twice, WB3 (20mM Tris-HCl pH7.5, 150mM NaCl) six times. Proteins were eluted in WB3 with 150 ng/µl of 3× FLAG peptide) for 30 min at 4°C with shaking. Purified proteins were resolved by SDS-PAGE and stained with Coomassie Brilliant Blue to verify protein purity. Protein content was calculated by densitometry, using a standard curve with bovine serum albumin (BSA).
ATPase assay. NSF ATPase activity was quantified using the Malachite Green Assay by measuring the release of inorganic phosphate (Pi) due to the ATP hydrolysis with spectrophotometer as previously described (Belluzzi et al. 2016) . 216 nM NSF was incubated with different ATP Size Exclusion Chromatography (SEC) and dot blot analysis. SEC was performed as previously described (Belluzzi et al. 2016) . Briefly, Strep-FLAG NSF WT and T465D transfected HEK-293T cells were lysed in 0.5ml of lysis buffer containing 0.06% (v/v) Triton X-100 and centrifuged. Cell lysates were separated on a Superose 6 10/300 column (Ge Healthcare, Waukesha, WI, USA) preequilibrated with 20mM Tris-HCl pH7.5, 150mM NaCl and 0.06% (v/v) Triton X-100. The flow rate used was 0.5ml/min. Fractions of 0.25ml were collected and spotted onto a nitrocellulose membrane and analyzed by dot blot. Densitometric analysis was performed by using ImageJ program.
Western-blotting. Protein samples were resolved on to 10-15% Tris-glycine polyacrylamide gels in SDS/Tris-glycine running buffer. Solubilized proteins were transferred to nitrocellulose or polyvinylidenedifluoride (PVDF) membranes in blotting buffer containing 10% methanol. The membrane was saturated for 1 h at RT in 5% nonfat dry milk in Tris-buffered saline and 0.1% Triton (TBS-T) and then incubated with the primary antibody in saturating solution for 90 min at RT. The unbound primary antibody was sheets was washed out in TBS-T (3x10 min) at RT and the membrane was incubated for 1 h at RT with horseradish peroxidase-conjugated anti-mouse or antirabbit IgGs. After 3 washes in TBS-T 10 min/each at RT, the immunoreactive proteins were visualized using enhanced chemioluminescence plus (ECL+, GE Healthcare, Little Chalfont, England). Densitometric analysis was carried out using Image J software.
Structure analysis. The Cryo-EM structure of NSF hexamer was downloaded from the PDB database, and the structural analysis was performed using the program PyMOL (http://www.pymol.org/). All the structural diagrams were prepared using the program PyMOL.
Statistical analysis and guidelines
All data are expressed as mean ± standard error of the mean (S.E.). The normality of data distributions was determined using the D'Agostino and Pearson omnibus normality test, followed by an unpaired Student's t test (two classes) or ANOVA followed by Tuckey's post-hoc test (more than two classes). The indication of number of experiment (n) and level of significance (p) are indicated throughout the text. All methods were performed in accordance with the relevant guidelines and national regulations.
List of expressing vectors
HA-Ubiquitin (pcDNA3.1), HA-K48R Ubiquitin (pcDNA3.1); HA-K63R Ubiquitin (pcDNA3.1) HA-K29,48,63R Ubiquitin (pcDNA3.1) (kind gifts by Dr. Simona Polo, IFOM); LRRK2 K1906M GFP (pcDNA3.1), LRRK2 G2019 GFP (pcDNA3.1) [ described in (Gloeckner et al. 2006 ); Strep-FLAG hNSF WT (pcDNA3.1) [ described in (Belluzzi et al. 2016) Wild-type and hG2019S mice were profiled for motor and cognitive abilities at 3, 6, 12 and 18 month. 6 and 12 months-old hG2019S mice are characterized by an impaired motor coordination and cognitive performance. In detail, we measured spontaneous motor activity in terms of number of horizontal (A) and vertical counts in 3 hours, time to cross a 6-mm width beam (C), time to reach the ground from a supra-elevated platform (D), time spent on rotarod running at 12 rpm (E) or 32 rpm (G), total resistance on 12 rpm running rotarod (F), and ability to recognize novel object compared to the familiar one (H). Data are shown as mean ±SEM .E; n=7-18. * p<0.05, ** p<0.01, *** p<0.001,****p<0.0001 versus aged-matched wild-type (two-way ANOVA, Bonferroni or Student's t post-hoc test). Post-mortem analysis of nigra specimen shows that NSF decorates α-synuclein positive lewy bodies and lewy neurite in G2019S PD patients (C). The table lists the numer of α-synuclein positive structure (a-syn +) positive for NSF staining (NSF +) and the relative percentage (%) in a 4 iPD and 2 GS patients (D). Induced dopaminergic neurons differentiated from two independent G2019S patients (G2019S 1 and 2) as well as gene-corrected counterpart (GC 1 and 2) were assayed by filter retardation assay to isolate high-molecular weight form of NSF (HMW) or by dotblot to measure total NSF protein (total) (E). The graphs report NSF aggregation expressed as HMW fold over total NSF (F). Data are shown as mean ±SEM, n=8. ** p<0.001 versus wild-type, ANOVA. DIV14 cortical cultures from wild-type or hG2019S mice were assayed by filter retardation assay to isolate high-molecular weight form of NSF (HMW) or by dot-blot to measure total NSF protein (G). The graphs report NSF aggregation expressed as HMW fold over total NSF. Data are shown as mean ±SEM, n=8. * p<0.05 versus wild-type (H). NSF accumulates in aggregates in substantia nigra and striatum in 6-months hG2019S LRRK2 mice. Scale bar= 10μm (I). The biochemical analysis of brain homogenate shows that NSF is resistant to proteinase K degradation in sample prepared from of 6-months old hG2019S mice. The amount of not-digested NSF decreases upon exposure to increasing concentrations of proteinase K (PK) in samples obtained from wild-type brains. Arrowhead indicates the band corresponding to full length NSF (J). The graphs report the amount of full length NSF protein expressed as optical density after digestion with 0.5 μ g/ml proteinase K. Data are shown as mean ±SEM, n=8. * p<0.05 versus wild-type (K). NSF accumulates in perinuclear aggregates decorated by LC-3 (L) and p62 (M) in DIV14 cortical neurons prepared from hG2019S mice. Images are shown in pseudo color (NSG green, LC-3 and p62 red, DAPI blue). Scale bar= 10μm. Figure 3. LRRK2 phosphorylation induces NSF aggregation. NSF aggregates in G2019S LRRK2 cellular models independently from proteasome activity. Wild-type and hG2019S DIV14 cortical neurons were treated with 100nM MG-132 or vehicle (DMSO) for 48 hours and then assayed by filter retardation assay to isolate high molecular weight (HMW) form of NSF or by dotblot to measure total NSF protein. NSF appears in HMW aggregates in wild-type neurons upon proteasome impairment and in vehicle treated hG2019S neurons (A). The graphs report NSF aggregation expressed as HMW fold over total NSF. Data are shown as mean ±SEM, n=8. *** p<0.001 versus wild-type, same treatment, ## p<0.01 versus DMSO, same genotype ANOVA (B). (D). LRRK2 phosphorylation influences NSF aggregation. We assayed the solubility profile of NSF in sample prepared from N2A cell over-expressing LRRK2 K1906M or LRRK2 G2019S variants and treated with vehicle (DMSO) or the LRRK2 kinase inhibitor GSK2578215A (GSK, 0.2 μΜ, 18 hours) (C). The graphs report the amount of NSF present in the Triton-X100 insoluble fraction, expressed as fold over total NSF. Data are shown as mean ±SEM, n=7. ** p<0.01 versus wild-type, same treatment; # p<0.05 versus G2019S DMSO, ANOVA (D). HEK293 cell over-expressing Strep-FLAG-NSF wild-type or phosphomimetic T645D isoform and treated with vehicle (DMSO) or MG-132 (10 μΜ, 18 hours) were assayed by filter retardation assay to isolate high molecular weight (HMW) form of NSF or by dot-blot to measure total NSF protein (E). The graphs report NSF aggregation expressed as ratio of HMW over total NSF optical density. Data are shown as mean ±SEM, n=5. ** p<0.01 versus wild-type, same treatment (F). The combined ribbon, stick and sphere representation showing the overall architecture of NSF hexamer structure from human (PDB ID: 3J94) as well as the positions of T645 and two bound ATP molecules in one NSF monomer. In this drawing, the six NSF monomers are shown in different colors, and the side chain of T645 is shown in the sphere mode and the bound ATP in the stick mode. The missing region between residue 456 and 479 in the NSF monomer is represented by a dashed pink line (G). The enlarged view of a NSF monomer in blue in panel G. Notably, the side chain of T645 is very close to the bound ATP molecule on the D2 domain (H). We assayed the solubility profile of FLAG-and HA-NSF in sample prepared from HEK293 cell over-expressing wild-type or phosphomimetic T645D Strep-FLAG-NSF isoform together with HA-NSF wild-type. Strep-FLAG NSF T465D is present in the Triton-X100 insoluble fraction and sequesters HA-NSF wild-type (I). The graphs report the amount of FLAG-NSF (J) and HA-NSF (K) present in the Triton-X100 insoluble fraction, expressed as fold over total NSF. We transfected in HEK293T cells myc-ubiquitin wild-type, K48R, K63R or K29/48/63 R together with Strep-FLAG-NSF WT or T645D. We purified on streptavidinbeads NSF protein and assessed ubiquitination level by western-blotting with anti-myc antibody. Arrowheads indicate putative NSF low molecular weight fragments detected by anti-FLAG antibody (L). The graphs report NSF ubiquitination in presence of myc-ubiquitin wild-type, calculated as anti-myc optical density normalized versus total NSF yield (M) and NSF fragmentation, expressed as ratio of low molecular weight NSF fragments over high molecular weight NSF optical density (N). Data are shown as mean ±SEM, n=7. ** p<0.01 versus wild-type, T-test.The graphs report NSF ubiquitination calculated as anti-myc optical density normalized versus total NSF wild-type (O) or T645D (P) yield and expressed as fold over ubiquitin wild-type condition and NSF fragmentation, expressed as ratio of low molecular weight NSF fragments over high molecular weight NSF wild-type (Q) or T645D (R) optical density and expressed as fold over ubiquitin wild-type condition. Data are shown as mean ±SEM, n=7. *, p<0.01, ** p<0.01 versus ubiquitin wild-type, one-sample T-test. Representative images of DIV14 Wildtype and hG2019S cortical neurons transduced at DIV4 with mCherry expressing viruses (control) or viruses co-expressing mCherry and wild-type Strep-FLAG NSF WT, phospho-null variant T645A or T645D. Where indicated, cells were chronically treated from DIV4 to DIV14 with DMSO or GSK2578215A (GSK, 0.2 μM, every two day). Cell were then processed for imaging purposes at DIV14, scale bar= 40um (A). The graph reports the number of neurite per neuron. Data are shown as mean ±SEM, n=14. *** p<0.001 versus NSF WT in wild-type neuron, °°° p<0.001 versus control infection in wild-type neuron, ## p<0.01 versus NSF WT in hG2019S neurons DMSO, ANOVA (C). Neuronal cultures were infected and treated as above and then processed for MTT assay at DIV14. Graph reports toxicity, expressed as 100-relative viability. Data are shown as mean ±SEM, n=18. ** p<0.01 versus NSF WT in wild-type neurons, # p<0.01 versus versus NSF WT in wild-type neurons DMSO,°° p<0.001 versus control infection in wild-type neuron, ANOVA (C). Figure 5 . Trehalose treatment rescues histochemical pathological hallmark of hG2019S mice in substantia nigra. Wild-type and hG2019S mice were treated starting at 5 month with trehalose (1% in drinking water) and processed for imaging analysis at 6-month. Nigra sections were stained with anti NSF, anti TH and anti cleaved caspase 3 antibodies and counterstained with hematoxylin to visualize nuclei. hG2019S mice are characterized by NSF aggregation and caspase-3 cleavage in nigra. Trehalose treatment reduces NSF aggregation and cleaved-caspase 3 signal, scale bar = 50 μm (A). The graph reports number of NSF aggregates (B), TH optical density (C) and number of caspase-3 positive cells (D) detected in 0.1 mm 2 area. Data are shown as mean ±S.E, n=6. *** p<0.001 versus wild-type, same treatment, $$$ p<0.001 versus water, same genotype, ANOVA. Figure 6. Trehalose treatment rescues histochemical pathological hallmark of hG2019S mice in striatum. Wild-type and hG2019S mice were treated starting at 5 month with trehalose (1% in drinking water) and processed for imaging analysis at 6-month. Striatal sections were stained with anti NSF, anti TH and anti cleaved caspase 3 antibodies and counterstained with hematoxylin to visualize nuclei (A). The graph reports number of NSF aggregates (B), TH optical density (C) and number of caspase-3 positive cells (D) detected in 0.1 mm 2 area. Data are shown as mean ±S.E, n=6. *** p<0.001 versus wild-type, same treatment, $$$ p<0.001 versus water, same genotype, ANOVA. Figure 7 . Trehalose treatment rescues histochemical pathological hallmark of hG2019S mice in cortex and hippocampus. Wild-type and hG2019S mice were treated starting at 5 month with trehalose (1% in drinking water) and processed for imaging analysis at 6-month. Brain sections encompassing cortical area or hippocampus were stained with anti NSF and anti cleaved caspase 3 antibodies and counterstained with hematoxylin to visualize nuclei. hG2019S mice are characterized by NSF aggregation and caspase-3 cleavage in cortex and hippocampus. Trehalose treatment reduces NSF aggregation and cleaved-caspase 3 signal (A). The graph reports number of NSF aggregates in cortex (B) and hippocampus (C) as well as number of caspase-3 positive cells in in cortex (D) and hippocampus (E) detected in 0.1 mm 2 area. Data are shown as mean ±S.E, n=5. *,
